Follow the 바이오노트 stock price and the full management transaction log of the company, a listed equity based in South Korea. Shares are listed on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 바이오노트 has recorded 31 insider filings. Market capitalisation: €452.4bn. The latest transaction was filed on 29 May 2026 (Purchase). Among the most active insiders: 조영식. Every trade is openly available.
31
Insider Decl.
n/a
Thresholds
€1m
13 ops.
Buy Volume
n/a
1 ops.
Sell Volume
32Σ signal
Buys €1mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,336 of 29,062 companies
30.4
score / 100
Value
29
Quality
32
FCF yld1.3%
Earn yld-18%
EV/EBITDA·
ROE-7.8%
Gross mgn56%
Net mgn-74%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
BioNote es una empresa especializada en el sector de la salud y farmacéutico, cotizada en el mercado XKRX. Se enfoca en el desarrollo de productos biológicos y de diagnóstico.